Results: 2

1.
Figure 2.

Figure 2. From: A Phase 2 Trial of Ixabepilone Plus Cetuximab in First-Line Treatment of Metastatic Pancreatic Cancer.

Overall survival by acneiform rash (n = 54).

Caio M. Rocha Lima, et al. Gastrointest Cancer Res. 2012 Sep-Oct;5(5):155-160.
2.
Figure 1.

Figure 1. From: A Phase 2 Trial of Ixabepilone Plus Cetuximab in First-Line Treatment of Metastatic Pancreatic Cancer.

Overall survival, including 6-month survival rate (top) and progression-free survival (bottom).

Caio M. Rocha Lima, et al. Gastrointest Cancer Res. 2012 Sep-Oct;5(5):155-160.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk